# A Risk-Focused Approach to Managing a Pivotal Phase III Critical Care Project Using TrialMaster

(Case Study)



October 2018



### **Quality Management: Not Just RBM**



### Brief History

- Clinical Trials Transformation Initiative recommends Risk-based Monitoring
  - July 2011
- Draft FDA Guidance for Industry
  - August 2011
- Final FDA Guidance for Industry: A Risk-based Approach to Monitoring
  - August 2013
  - Guidance documents represent the FDA's current thinking..., "you can use an alternative approach if it satisfies the requirements..."
- Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6 (R2)
  - November 2016
- ICH E6 (R2) Good Clinical Practice: Integrated Addendum to ICH E6 (R1) Guidance for Industry – catalyst for widespread application of "Quality Management Systems" for clinical trial industry
  - March 2018



- Quality Management [Section 5, E6R2]
  - Focus on activities essential to ensuring human subject protection and the reliability of the trial results
  - Design of protocols, tools and procedures for data collection and processing should be clear, concise and consistent
  - Methods used to control quality should be proportionate to the risks
- Quality Management System (QMS) should use a risk-based approach:
  - Critical process and data identification <sup>(1)</sup>
  - Risk identification <sup>(2)</sup>
  - Risk evaluation <sup>(3)</sup>
  - Risk control <sup>(4)</sup>
  - Risk communication <sup>(5)</sup>
  - Risk review <sup>(6)</sup>
  - Risk reporting<sup>(7)</sup>

### **Quality Management: Trial Level**



- Joint identification of critical data/key risk factors (1, 2, 3)
- Establishment of initial quality thresholds <sup>(3, 4)</sup>
- Risk & Issues Mgmt determined <sup>(4, 5, 6)</sup>
- Central Monitoring Summaries <sup>(5, 6, 7)</sup>
- Escalation & action planning; summarization of trends <sup>(5, 6, 7)</sup>
- Ongoing adjustments to QMA; e.g., site mgmt actions, plan revisions, re-training, etc. <sup>(1, 2, 3, 4, 5, 6, 7)</sup>



- Study Plans focus on data & procedures with greatest potential impact on outcomes of study <sup>(4, 5, 6, 7)</sup>
- Data and trend reports developed and review schedules determined <sup>(6, 7)</sup>
- Roles & responsibilities defined for crossfunctional data/risk evaluations <sup>(4)</sup>
- In-house/central data monitoring + field experiences = risk analysis, determine on-site focus (5,6)
- Pool of on-site visits applied based on site risk composite scores from Central Monitoring Logs (5,6)

### **Quality Management: Trial Level**







### **Data and Procedures Identified as Critical to Quality**

- Required data collection and study procedures that have the greatest potential to impact interpretation of the data have been assessed. Site training, traditional on-site monitoring, and centralized monitoring will be performed in order to reduce or mitigate potential errors in the following categories:
  - A. Eligibility Criteria
  - B. IP Administration
  - C. Adverse Events/Serious Adverse Events
  - D. Delayed Cerebral Ischemia
  - E. Radiology Assessments
  - F. Neurologic Assessments
  - G. Compliance with and accurate completion of the GOSE (Extended Glasgow Outcome Scale) and MoCA (<u>Montreal Cognitive Assessment</u>)
  - H. Compliance with maintaining the blind in accordance with the protocol and the Site Blinding Plan
- These data and procedures will be targeted for in-house data review and be the focus for source document review and verification during on-site visits.



### **Critical Forms for SDV/SDR**

Adverse Events
Angiogram
Aneurysmal Subarachnoid Hemorrhage History
CT Scan
Delayed Cerebral Ischemia
Extended Glasgow Outcome Scale
Inclusion/Exclusion Criteria Not Met
Intraventricular IP Administration
Modified Glasgow Coma Scale
Montreal Cognitive Assessment
aNIHSS
Prior and Concomitant Medications
Prior and Concomitant Procedures/Therapies
World Federation of Neurological Surgeons Assessment
Subject Information
Disposition
Hospitalization

### **Case Study: Central Monitoring Reports**



Site Performance Assessment

Rated on 3 point scale: 0 = no action required 1 = attention needed

- 2 = immediate action required
- Experience of PI and staff (rated initially, then as needed based upon changes or turnover of key staff)
- PI Involvement
- Site Responsiveness



In-House Monitoring Records

Similar ratings applied to routinely monitored data sets based upon:

- Key risk indicators
- Performance metrics
- Outliers or trends identified

The two components are evaluated together to determine:

• Frequency of interim visits • Other actions/mitigations



#### Section 1 – Site Performance Indicators (SPI)

ltem #	SP	0	1	2
1.1	<ul> <li>Rate prior Sponsor/RPG Experience with site. (This score is determined by the CRA and should remain the same throughout the study. Refer to CMR Log for previously assigned scores. Newly activated sites that have not yet received a score will need one assigned by the CRA at this time).</li> <li>This score is assessed after the SIV occurs and reflects a rating based on Sponsor/RPG prior experience with the site. The score should remain the same throughout the study.</li> </ul>			
1.2	<ul> <li>Rate the experience of the PI and staff and site turnover rate. This should be assessed initially, and thereafter when there are staff changes in the study team.</li> <li>(This score is determined by the CRA).</li> <li>O for no staff changes since the previous CMR</li> <li>1 indicates moderate concerns about site staff experience or turnover, requiring discussion with the investigator or study coordinator; staff changes that do not impact the site's ability to enroll and/or enter data.</li> <li>2 indicates significant concerns about the site staff experience or turnover, requiring escalation to the PM for consideration of actions such as contact with the investigator, or escalation to Sponsor; PI, or staff changes that impact enrollment and/or data entry.</li> </ul>			
1.3	<ul> <li>Rate impact of changes in key facility, equipment, systems, or procedures at the site. (This score is determined by the CRA).</li> <li>O for no staff changes since the previous CMR</li> <li>1 indicated changes presenting moderate potential issues (e.g. change in local labs), requiring discussion with the investigator, study coordinator, or pharmacist; changes that do not impact enrollment or data entry</li> </ul>			



#### Section 2 – In-House Data Monitoring (IHDM) (Key Risk Indicators – Data Operations)

Item #	KRI	0	1	2
2.1	<ul> <li>Rate the time to entry of eCRF data. (This score is determined by the CRA and is based on CRA findings from desktop monitoring, site contacts, and emails sent by the IHDM CRA about missing eCRF data).</li> <li>0 = average ≤3 business days from subject visit to data entry. No action required.</li> <li>1 = average of 3-10 business days from subject visit to data entry. Requires a discussion with study coordinator.</li> <li>2 = average of &gt;10 business days from the subject visit to data entry. Requires escalation to the PM for consideration of other actions, such as contact with investigators.</li> </ul>			
2.2	<ul> <li>Provide a rating based on the percentage of eCRF pages that have queries. (This score is determined by the IHDM CRA). (Reference the CRF Status Report) – Follow instructions.</li> <li>0 = 0.5% of pages have queries, across the site. No action required.</li> <li>1 = 6-10% of pages have queries, across the site. Requires discussion with study coordinator.</li> <li>2 = &gt;10% of pages have queries, across the site. Requires escalation to PM for consideration of other actions, such as contact with investigators.</li> </ul>			
2.3	<ul> <li>Provide a rating based on average query resolution time by site. (This score is determined by the IHDM CRA).</li> <li>0 = &lt;30 days. No action required.</li> <li>1 = 30-60 days. Requires discussion with study coordinator.</li> </ul>			



#### Section 3 – In-House Data Monitoring (Key Risk Indicators – Study Metrics & Trends)

Item #	KRI	0	1	2
3.1	<ul> <li>Provide a rating based on the average number of AEs per subject at the site compared to the average across the study. (This score is determined by the IHDM CRA). (Refer to CMR Metrics spreadsheet).</li> <li>0 = an AE incidence within X% of the average across all sites. No action required.</li> <li>1 = an AE incidence between X% and up to one standard deviation less than or greater than the average across all sites. Requires a discussion with investigator.</li> <li>2 = an AE incidence greater than one standard deviation less than or greater than the average across all sites. Requires escalation to the PM for considerations of other actions, such as further contact with the investigator contact with the Medical Monitor, or escalation to Sponsor.</li> </ul>			
3.2	<ul> <li>Provide a rating based on the average number of SAEs per subject at the site compared to the average across the study. (This score is determined by the IHDM CRA). (Refer to CMR Metrics spreadsheet).</li> <li>0 = an SAE incidence with X% of the average across all sites. No action required.</li> <li>1 = an SAE incidence between X% and up to one standard deviation less than or greater than the average across all sites. Requires a discussion with investigator.</li> <li>2 = an SAE incidence greater than one standard deviation less than or greater than the average across all sites. Requires than the average across all sites compared to the PM for considerations of other actions, such as further contact with the investigator contact with the Medical Monitor, or escalation to Sponsor.</li> </ul>			
3.3	Provide a rating based on the AE casualties per subject at the site compared to the average across the study. (This score is determined by the CRA). (Refer to CMR Metrics spreadsheet).			

### **Case Study: CMS Quarterly Comparisons**





Confidential



Need for De-Identified Copies of Assessments to be Available Immediately for Third Party Review

**Protocol Specific Events with Specific Criteria** 

**Data-Heavy Assessments and Scales** 

**Complex Randomization Process** 

### **Case Study: Need for De-Identified Copies of Assessments**



- A field was added via Mid-Study Change that allowed PDFs or JPG files to be uploaded directly into TrialMaster by the Site Coordinators
- Third party reviewers with View Access to EDC were able to compare data directly from source document assessment/scale to confirm it was scored appropriately and entered in EDC correctly



Extended Glasgow Outcome Scale		(1)
		<del>()</del>
Was a GOSE performed?	🔍 No 🛛 Yes	•
Date of Assessment	13/JUL/2017 DD/MON/YYYY(EN)	•
Respondent	2 = Patient plus relative/friend/caretaker	•
Attach all GOSE worksheets and questionnaires associated with this visit.	Report.	

### **Case Study: Need for De-Identified Copies of Assessments**



### **ADVANTAGES**

- Third party reviewers were able to view source almost immediately
- A dedicated fax line and/or email address did not need to be set up and monitored
- Listings can be run to easily identify subjects missing their uploaded source documents

### **POTENTIAL RISKS**

- Ensure documents are truly de-identified prior to uploading
- Documents are often not scanned properly and follow-up with Study Coordinators is needed to ensure all pages are visible and complete



## Sponsor provided complicated criteria for what events met the criteria of a DCI:

#### Diagnosis of Delayed Cerebral Ischemia

DCI will be defined by the following:

- For subjects in whom the neurologic scales are assessable: a decrease of at least 2 points on the mGCS or an increase of at least 2 points on the aNIHSS, lasting for at least 2 hours, where other medical or surgical causes (exclusion of any other explanation for the deterioration, such as (increasing) hydrocephalus, recurrent bleeding, seizures (electroencephalography performed in case of suspicion of seizures unless obvious clinically), an infectious disease with associated decrease in consciousness level, hypoglycemia (<3.0 mmol/L) or hyponatremia (<125 mmol/L), metabolic encephalopathy caused by renal or hepatic failure or any other possible cause for deterioration) are excluded.<sup>17</sup> The deterioration is measured relative to the best scores attained after aneurysm repair.
- For subjects in whom the neurologic scales are not assessable: radiological evidence and clinical judgement.

Subjects with suspected DCI should have appropriate radiological investigations perfor Investigations should be performed to exclude other causes of deterioration. Review physical examination, CT/CTA and bloodwork are recommended as a minimum. angiography/CT perfusion (CTA/CTP) is particularly suggested when endovas being considered, the diagnosis of DCI is particularly uncertain such as subj

assessable on neurological scales deterioration may be multifactori ations, graphy herapy is

### "...and clinical judgement."

### **Case Study: Protocol Specific Events with Specific Criteria**





Two main questions were utilized in the Dynamic Rule: "Was DCI Diagnosed after randomization?" and "Was subject assessable?



Delayed Cerebral Ischemia			
		Codelist	
Item Name/SAS Variable	Front End Form Question Text	Control Type	Name
[DCI]	1 of 1		
	Was DCI diagnosed after		
DCIPERF[DCIPERF]	randomization?	RadioButton	NY
DCIASSES[DCIASSES]	Was subject assessable?	RadioButton	NY



Delayed Cerebral Ischemia		
Was DCI diagnosed after randomization?	O No	• Yes
Was subject assessable?	No	O Yes

### **Case Study: Protocol Specific Events with Specific Criteria**



Was DCI diagnosed after randomization?

Was subject assessable?

elayed Cerebral Ischemia			6
			0
Was DCI diagnosed after randomization?	O No	O Yes	¢
Was subject assessable?	0 No	O Yes	•
Check one or both			
Decrease of two or more points in mGCS lasting for more than 2 hours where other medical causes are excluded			¢
Increase of 2 or more points in aNIHSS lasting for more than 2 hours where other medical causes are excluded.			¢



### This was accomplished by the use of Dynamic Rules using HIDE Edits

					Error/Warning
Edit Numbe 🝸	Visit Name 👻	SAS Variable 🝸	Edit Type 🖓	Condition 🗸	Message Text 🛛 🝸
				DCIPERF is not Yes or DCITERM = null or DCINON	
DCI42	Delayed Cerebral Ischemia	DCISPEC	HIDE	is checked or DCIOTHER is not checked	NO ERROR MESSAGE
				DCIPERF is not Yes or DCITERM = null or DCISER	
DCI57	Delayed Cerebral Ischemia	DCIDESC	HIDE	is not Yes	NO ERROR MESSAGE
				DCIPERF is not Yes or DCITERM = null or DCISER	
DCI58	Delayed Cerebral Ischemia	Datagroup [DCI4]	HIDE	is not Yes	NO ERROR MESSAGE
				DCIPERF is not Yes or DCITERM = null or DCISER	
DCI62	Delayed Cerebral Ischemia	DTHDAT	HIDE	is not Yes or AESDTH is not checked	NO ERROR MESSAGE
				DCIPERF is not Yes or DCITERM = null or	
DCI94	Delayed Cerebral Ischemia	DCISPEC3	HIDE	DCIACN2 does not equal Other	NO ERROR MESSAGE
				DCIPERF is not Yes or DCITERM = null or DCIREL	
DCI96	Adverse Events	DCIRSPEC	HIDE	is not Suspected	This item is required.

Was DCI diagnosed after randomization?	O No	O Yes	Was DCI diagnosed after randomization?	O No	O Yes
Was subject assessable?	O No	O Yes	Was subject assessable?	© No	O Yes



### The inverse was also accomplished using Dynamic Rules with ENABLE Edits.

					Error/Warning
Edit Numbe 🔻	Visit Name 👻	SAS Variable 🔻	Edit Type 🖅	Condition 🍼	Message Text 💌
DCI04	Delayed Cerebral Ischemia	DCILBL	ENAB	DCIPERF = Yes	NO ERROR MESSAGE
DCI06	Delayed Cerebral Ischemia	DCIGCS	ENAB	DCIPERF = Yes and DCIASSES = Yes	NO ERROR MESSAGE
DCI07	Delayed Cerebral Ischemia	DCINIHSS	ENAB	DCIPERF = Yes and DCIASSES = Yes	NO ERROR MESSAGE
DCI08	Delayed Cerebral Ischemia	DCILBL2	ENAB	DCIPERF = Yes	NO ERROR MESSAGE
DCI09	Delayed Cerebral Ischemia	DCINONE	ENAB	DCIPERF = Yes	NO ERROR MESSAGE
DCI11	Delayed Cerebral Ischemia	DCICTA	ENAB	DCIPERF = Yes and DCINONE is not checked	NO ERROR MESSAGE
DCI12	Delayed Cerebral Ischemia	DCMRIMRA	ENAB	DCIPERF = Yes and DCINONE is not checked	NO ERROR MESSAGE

Was DCI diagnosed after randomization?	O No	<b>⊙</b> Yes
Was subject assessable?	O No	⊚ Yes
Check one or both		
Decrease of two or more points in mGCS lasting for more than 2 hours where other medical causes are excluded	N	
Increase of 2 or more points in aNIHSS lasting for more than 2 hours where other medical causes are excluded.	V	

### **Case Study: Data-Heavy Assessments and Scales**



D

VS SD -MD -MD + GR -GR +

- Study endpoints depended on data collected from two complex scales
- Extended Glasgow Outcome Scale (GOSE) utilizes 9 questions in a structured interview format to rate subject's status:

POST DISCHARGE	1
STRUCTURED INTERVIEW FOR GOSE	2
Respondent: 0 = Patient alone 1 = Relative/friend/caretaker alone 2 = Patient plus relative/friend/caretaker	3
Respondent: 0 = Patient alone 1 = Relative/friend/caretaker alone 2 = Patient plus relative/friend/caretaker	4
Conciousness:	5
1. Is the head-injured person able to obey simple commands or say any words?	6
Yes No (VS)	7
Note: anyone who shows the ability to obey even simple commands or utter any word or communicate specifically in any other way is no	8
longer considered to be in vegetative state. Eye movements are not reliable evidence of meaningful responsiveness. Corroborate with nursing staff and/or other caretakers. Confirmation of VS requires full assessment.	~
Independence at home:	
2a. Is the assistance of another person at home essential every day for some activities of daily living?	
Yes No (VS) If no: go to 3	
Note: for a NO answer they should be able to look after themselves at home for 24 hours if necessary, though they need not actually look after themselves. Independence includes the ability to plan for and carry out the following activities: getting washed, putting on clean clothes without prompting, preparing food for themselves, dealing with callers and handling minor domestic crises. The person should be able to carry out activities without needing prompting or reminding and should be capable of being left alone overnight.	
2b. Do they need frequent help of someone to be around at home most of the time?	
Yes (lower SD)     No (upper SD)	
Note: for a NO answer they should be able to look after themselves at home up to eight hours during the day if necessary, though they need not actually look after themselves	

	2	vegetative state	
ı I	3	Lower severe disability	
	4	Upper severe disability	
	5	Lower moderate disability	
L I	6	Upper moderate disability	
L I	7	Lower good recovery	
L I	8	Upper good recovery	
Ľ			

Death

In material on atom

### **Case Study: Data-Heavy Assessments and Scales**



### Derivations utilized to facilitate correct data entry of scale rating

Edit Number 🛛 🔽	Visit Name 💌	SAS Variable	Edit Type 🛛 🗐	Condition 🔻
				When EGOPERF = Yes and EGO01 = 'No = 2 (VS)', populate EGORRES with 2 -
				When EGOPERF = Yes and EGO01 = Yes and EGO02B = 'Yes = 3 (lower SD)'.
				populate EGORRES with 3 - Lower SD.
				When EGOPERF = Yes and EGO01 = Yes and EGO02B = 'No = 4 (upper SD)', or
				EGO03A = 'No = 4 (upper SD)', or EGO04A = 'No = 4 (upper SD)', populate EGORRES
				with 4 - Upper SD.
				When EGOPERF = Yes and EGO01 = Yes and EGO05B = 'Able to work only in a
				sheltered workshop or non-competitive job or currently unable to work = 5 (Lower
				MD)', or EGO06B = 'Unable to participate: rarely, if ever take part = 5 (Lower MD)',
				or EGO07B = 'Constant – Daily and Intolerable = 5 (Lower MD)', populate EGORRES
				with 5 - Lower MD.
				When EGOPERF = Yes and EGO01 = Yes and EGO05B = 'Reduced work capacity = 6
				(Upper MD)', or EGO06B = 'Participate much less: less than half as often = 6 (Upper MD)', or EGO07B = 'Frequent – Once a week or more, but tolerable = 6
				(Upper MD), or EGOUVE - Frequence - Once a week of more, but tolerable - 6 (Upper MD)', populate EGORRES with 6 - Upper MD.
				(opper MD), populate EdotAES with 0 - opper MD.
				When EGOPERF = Yes and EGO01 = Yes and EGO06B = 'Participate a bit less: at
				least half as often as before the hemorrhage = 7 (Lower GR)', or EGO07B =
				'Occasional - Less than weekly = 7 (Lower GR)' or EGO08A = 'Yes = 7 (Lower GR)',
				populate EGORRES with 7 - Lower GR.
				When EGOPERF = Yes and EGO01 = Yes and EGO08A = 'No = 8 (Upper GR)',
				populate EGORRES with 8 - Upper GR.
				If any the fields listed above is null, do not derive EGORRES. EGORRES is to be
GOSE67	Day 30, Day 90, Unscheduled	EGORRES	DVA	derived based on lowest number selected.

CONSCIOUSNESS			-01	
CONSCIOUSNESS:				
1. Is the subject able to	obey simple commands or say any words?	● Yes  ◎ No = 2 (VS)	•	
			0	
Overall Rating	2 - Vegetative State		Θ	

### **Case Study: Complex Randomization Process**



- Pre-Randomization and Randomization process was lengthy
- Pre-Randomization data used for stratification and could not be changed once established
- Sponsor wanted to minimize data entry errors by EDC receiving data imports from IRT via application programming interface (API) call
- Data included:
  - Subject Number
  - Informed Consent: Date & Time
  - Randomization: Date & Time
  - Randomization Number
  - Demographics: Date of Birth, Age, & Sex
  - World Federation of Neurological Surgeons Assessment (WFNS) data



### **Case Study: Complex Randomization Process**





Confidential

### **Integrated Quality Management**



